Variables | Total (n = 221) | Cohort | |||||
---|---|---|---|---|---|---|---|
ST17 (n = 52) | non-ST17 (n = 169) | P value | |||||
Virulence factors | |||||||
esp+hyl+ | 179 (80.9) | 51 (98.1) | 128 (75.7) | < 0.001 | |||
Age/sex/BMI | |||||||
Age (mean ± SD) | 62.3 ± 14.5 | 64.7 ± 14.5 | 61.5 ± 15.0 | 0.752 | |||
Male | 132 (59.7) | 28 (53.8) | 104 (61.5) | 0.323 | |||
BMI ≥ 25 kg/m2 | 48 (21.7) | 10 (19.2) | 38 (22.5) | 0.619 | |||
Underlying condition | |||||||
Decompensated LC | 36 (16.3) | 6 (11.5) | 30 (17.8) | 0.289 | |||
AKI requiring RRT | 58 (26.2) | 10 (19.2) | 48 (28.4) | 0.189 | |||
Diabetes mellitus | 57 (25.8) | 45 (26.6) | 12 (23.1) | 0.609 | |||
Cancer | 67 (30.3) | 18 (34.6) | 49 (29.0) | 0.441 | |||
Hematologic malignancy | 44 (19.9) | 6 (11.5) | 38 (22.5) | 0.084 | |||
Liver transplantation | 15 (6.8) | 0 (0.0) | 15 (8.9) | 0.026 | |||
Neutropenia | 42 (19.0) | 8 (15.4) | 34 (20.1) | 0.447 | |||
CCI (Median, IQR) | 3 (2–5) | 3 (1.25–4) | 3 (2–5) | 0.773 | |||
Invasive procedure/ICU | |||||||
Central venous catheter | 124 (56.1) | 95 (56.2) | 29 (55.8) | 0.955 | |||
Artificial airway | 57 (25.8) | 15 (28.8) | 42 (24.9) | 0.565 | |||
Intra-abdominal surgery | 21 (9.5) | 4 (7.7) | 17 (10.1) | 0.789 | |||
Parenteral nutrition | 114 (51.6) | 25 (48.1) | 89 (52.7) | 0.563 | |||
ICU Stay | 157 (71.0) | 35 (67.3) | 122 (72.2) | 0.497 | |||
Previous antibiotic use | |||||||
Ampicillin | 29 (13.1) | 5 (9.6) | 24 (14.2) | 0.392 | |||
Glycopeptide | 121 (54.8) | 33 (63.5) | 88 (52.1) | 0.149 | |||
3rd- or 4th-generation cephalosporin | 84 (38.0) | 16 (30.8) | 68 (50.2) | 0.219 | |||
Carbapenem | 123 (55.7) | 27 (51.9) | 96 (56.8) | 0.535 | |||
Piperacillin/tazobactam | 132 (59.7) | 29 (55.8) | 103 (60.9) | 0.506 | |||
Metronidazole | 33 (14.9) | 7 (13.5) | 26 (15.4) | 0.734 | |||
Fluoroquinolone | 68 (30.8) | 12 (23.1) | 56 (33.3) | 0.162 | |||
Aminoglycoside | 20 (9.0) | 7 (13.5) | 13 (7.7) | 0.266 | |||
Linezolid | 16 (7.2) | 3 (5.8) | 13 (7.7) | 0.768 |